Large language models in cancer: potentials, risks, and safeguards.

Abstract

This review examines the use of large language models (LLMs) in cancer, analysing articles sourced from PubMed, Embase, and Ovid Medline, published between 2017 and 2024. Our search strategy included terms related to LLMs, cancer research, risks, safeguards, and ethical issues, focusing on studies that utilized text-based data. 59 articles were included in the review, categorized into 3 segments: quantitative studies on LLMs, chatbot-focused studies, and qualitative discussions on LLMs on cancer. Quantitative studies highlight LLMs' advanced capabilities in natural language processing (NLP), while chatbot-focused articles demonstrate their potential in clinical support and data management. Qualitative research underscores the broader implications of LLMs, including the risks and ethical considerations. Our findings suggest that LLMs, notably ChatGPT, have potential in data analysis, patient interaction, and personalized treatment in cancer care. However, the review identifies critical risks, including data biases and ethical challenges. We emphasize the need for regulatory oversight, targeted model development, and continuous evaluation. In conclusion, integrating LLMs in cancer research offers promising prospects but necessitates a balanced approach focusing on accuracy, ethical integrity, and data privacy. This review underscores the need for further study, encouraging responsible exploration and application of artificial intelligence in oncology.